I imagine so. I thought a company was doing studies on this at Canaccord. Mimedx should partner with a company in the field.
Dr Cole is using Amniofix in comparison with PRP and from what I gather, doing studies. I have used PRP and believe Amniofix will easily win this comparison. I couldn't find the number, but thousands of hair graft procedures are performed in the US each year. Also, approximately 1.5 million skin injection like dermal fillers are performed in the US each year. I believe collagen-Amniofix injections should be a big groth area for MDXG. There are many untapped areas that will promote revenue growth for many years.
BLA approved for plantar fasciitis micronized Amniofix studies beginning sping 2015. Perhaps FDA approval for sale and marketing of proven therapy with sale to physicians using off label also by sring 2016. IMHO
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
11/28/2014 14,258,377 630,671 22.608265
Their pain will be exponential if they do not cover soon.
Agree. 2015 guidance should be a stimulus. They won't say it, but I think we push 200 million 2015. 2016 may blow the lid off if the injectable market gets going.
The food is very good, healthy and reasonably priced. The food seems better than Panera and ZOE'S was busier than a Panera in the same shopping center. I am looking to invest in ZOE'S as a long term investment. How many new stores are expected each year and will new debt be issued for expansion? Thanks for any help.
The new hire tells me time is short, I particularly like the expertise in mergers and acquisitions:
In his new role, Mr. Cashman will contribute his expertise to the Company's sales & marketing functions, strategic planning and all related revenue growth initiatives. "We are very pleased to have Chris join MiMedx. He is an executive with C-Level experience in both public and private healthcare organizations. Chris has extensive experience in the sales and marketing arena, but he also has excellent operational and general management experience. Beyond sales and marketing, he has expertise in global market commercialization, mergers and acquisitions, intellectual property development, regulatory pathways, and Medicare and commercial reimbursement. We are very fortunate already to have a number of executives within MiMedx that have General Management capabilities, and the addition of Chris will further complement this talent within our organization," said Parker H. "Pete" Petit, Chairman and CEO.
Report 11/25 at 4 PM for period ending 11/15. My guess is still around 15.6 million. The shorts oddly have not covered and will suffer their Waterloo fall of 2015.
Tim is a wound care doc and uses Epifix. I have also used Epifix. It works and there is research to prove it works. There are many products out there that are nothing but scaffolds for wound healing cells to crawl across. They don't work so well in tissue with poor vascularity. I have not tried AXGN, but you may want to listen to Tim and my advise if buy more MDXG and ride the winner to 20-25.
The just released study showed significant increases in wound healing and cost savings with Epifix vs Apligraf. This could significantly add to MDXG revenues in 2015. Needham raised price target to 12, but this might be a bit conservative.
95% regained erectile function at 6 months using Amniofix as a nerve wrap and only 50% without. Nerve function recovered earlier as 90% had regained erectile function at 3 months while only 40% without Amniofix. 100% of men will request Amniofix if given a choice. A new standard of care is created and those not receiving and having a bad outcome will be grounds for litigation.
More studies will follow, but there were 195,000 radical prostatectomies in the US in 2002 and more now. You will see 20 million in revenue from this in short order. This is basically for the robotic assisted radical prostectomies, but look for extension to all. Amniofix will be covered under the DRG and likely insurance companies will give it a separate procedure code after another study or two.
This is really big.
I don't think they make it. MDXG will consume the wound healing market with share also going to OSIR. Others will be toast.
Chris has extensive experience in the sales and marketing arena, but he also has excellent operational and general management experience. Beyond sales and marketing, he has expertise in global market commercialization, mergers and acquisitions, intellectual property development, regulatory pathways, and Medicare and commercial reimbursement. (Mergers and acquisitions, global market commercialization- sounds solid)
This stock should have a large pps increase over the next 1.5 years. If held in a taxable account, is there any strategy to shield capital gains other than selling losing tocks?